Clinical Trial Update: A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety, tolerability, and immunogenicity of a 13-valent pneumococcal conjugate vaccine in Japanese adults aged 65 and older has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Vaccines, Pneumococcal Conjugate Vaccine | Phase 3 | Status: COMPLETED | Results posted: 2013-09-20